Thyroid Eye Disease (TED)

• Research type

  Research Study

• Full title

  A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q3W) by intravenous (iv) infusion in patients suffering from active thyroid eye disease (TED)

• IRAS ID

  151288

• Contact name

  Daniel Ezra

• Contact email

  d.ezra@ucl.ac.uk

• Sponsor organisation

  River Vision Development Corporation

• Eudract number

  2014-000113-31

• ISRCTN Number

  N/A

• REC name

  London - South East Research Ethics Committee

• REC reference

  14/LO/0543

• Date of REC Opinion

  16 May 2014

• REC opinion

  Further Information Favourable Opinion